

# FOR IMMEDIATE RELEASE

## **Courtagen Life Sciences Receives New York State Clinical Laboratory Approval**

*Courtagen Life Sciences expands availability of clinical genetic testing for pediatric neurology and metabolic disorders to New York state.*

WOBURN, MA. January 21<sup>st</sup>, 2016, Courtagen Life Sciences, Inc., a CAP-certified CLIA laboratory and molecular information company, today announced that they have completed the comprehensive Clinical Laboratory Evaluation Program and received their clinical laboratory permit from the state of New York. With this license, Courtagen now offers its genetic tests in all 50 states, Canada, and other countries.

Courtagen's full catalog of next-generation sequencing test panels will now be available in New York state, including epiSEEK® tests for epilepsy and seizure disorders; devSEEK® and devACT® tests for developmental delay, intellectual disability, and autism spectrum disorders; nucSEEK® and mtSEEK® tests for mitochondrial disorders, and lysoSEEK™ test for lysosomal storage disorders. Additionally, Courtagen's unique rxSEEK™ Epilepsy test is also available, a pharmacogenomic test to evaluate how a patient may metabolize anti-epileptic drugs and alert physicians to potential medication issues or drug-drug interactions.

"Obtaining the New York state license is an important achievement for Courtagen, and we're very proud our operation has passed the rigorous New York inspection and approval process," said Brian McKernan, chief executive officer of Courtagen. "We have seen strong adoption by pediatric neurologists across the country for our services, and now we look forward to providing our highly accurate and clinically actionable tests to physicians and their patients in New York."

The diseases addressed with Courtagen's testing can be very complex, with many patients and their families on years-long diagnostic odysseys looking for answers. Courtagen's approach of using a comprehensive gene panels seeks to determine the root genetic cause of a neurological or metabolic condition to enable physicians to quickly and cost-effectively find the most suitable and effective course of treatment.

### **About Courtagen Life Sciences, Inc.**

Courtagen Life Sciences, Inc., located in Woburn, MA, is a CLIA/CAP certified molecular information company focused on the diagnosis of a range of neurological disorders. Courtagen operates a highly sophisticated Next Generation DNA Sequencing, bioinformatics, and clinical interpretation business. Courtagen's work helps physicians reveal the linkages between the genotypes and phenotypes of various neurological diseases. For more information, please visit <http://www.courtagen.com/>

Contact:  
Courtagen Life Sciences  
Mike Catalano  
press@courtagen.com  
877-395-7608

###